NEW YORK, February 20, 2013—Kantar Health, a leading global advisory and marketing research company, recently partnered with Roche Egypt to help bring the latest thinking in health economics and cost-effectiveness analysis to the country’s largest payer, the Health Insurance Organization (HIO).
Roche Egypt approached Kantar Health Egypt to look at applying health economics as the key tool for selecting medications for the HIO formulary. Kantar Health recommended an alternative approach that centered on running evidence-based workshops with key HIO stakeholders to raise awareness of health economics models and cost-effectiveness studies. This approach was intended to build a strong dialogue among the three parties for agreeing on value-based pricing and preparing for 2017 as the target year for 100% coverage of the HIO in Egypt.
The first workshop, which included 60 physicians, pharmacists and key decision makers from the HIO, covered the evaluation of different treatments using various health economics models. Takeaway actions from the workshop included:
- The formation of new health economics department at the HIO directly reporting to its Chief Information Officer, Dr. Abdelrahman Alsaka
- The establishment of a health economics committee, comprising 10 stakeholders, to work on actions from the workshop, including developing a roadmap of standard operating procedures
- An undertaking from the HIO team, including key HIO department heads Dr. Mohsen George (head of medical affairs) and Dr. Sawsan Asaad (head of medical supply and pharmacies), to partner with Kantar Health in educating the rest of its departments on the use of cost-based health economics models in the decision-making process on an ongoing basis.
“We know that affordability is a major barrier to drug success in Egypt,” said Islam Anan, Senior Research Manager, Kantar Health. “We also understand that key local influencers have knowledge gaps and that engaging them in discussions on price concessions and other means of achieving market access prior to producing a health economics study is likely to improve their chances of success, which is why we took this approach.”
Sherif Abaza Market Access Head of Roche Egypt, said, “Kantar Health has acted as a true partner to Roche Egypt in this project, and we will continue to work together in the hope that our educational workshops will result in improved health economic modeling processes and a better healthcare set-up in Egypt.”
About Kantar Health (www.kantarhealth.com)
Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.
With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.
About Roche (www.roche.com)
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
All trademarks mentioned in this release are protected by law.
+1 314 529 3062